Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects

Trial Profile

Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Pimasertib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top